Company Profile
Novavax Stock Price, News & Analysis
- Ticker:
- NVAX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.74 USD (+0.52%)
Close
Last updated: August 6, 2026
1.68B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NVAX closed up 0.52% at $7.74. No new same-company headline was identified in the current news window.
Company overview
Business overview
Novavax is a vaccine company centered on protein-based immunization and respiratory-disease programs. Its story has been shaped by the challenge of turning platform science into durable commercial execution.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Novavax sits in specialty vaccine biotechnology.
Business Model Characteristics
The business depends on vaccine demand, partnerships, regulatory progress, and the ability to sustain a post-pandemic franchise.
Position Within the Biotechnology Landscape
Novavax is a vaccine catalyst name where commercial and regulatory updates can quickly shift sentiment.
Future catalysts
Novavax's catalysts are the COVID/flu-combo program, seasonal-vaccine partnerships, and royalty momentum from its vaccine platform. The company still needs the platform to keep broadening.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Novavax (NVAX)?
Novavax (NVAX) most recently closed at 7.74 USD, a +0.52% move versus the previous session.
What is the market cap of Novavax (NVAX)?
Novavax currently has a market capitalization of 1.68B USD on BioPharmSignal.
What does Novavax do?
Novavax is a vaccine company centered on protein-based immunization and respiratory-disease programs. Its story has been shaped by the challenge of turning platform science into durable commercial execution.
On which exchange is NVAX stock listed?
Novavax (NVAX) is associated with NASDAQ, United States, Biopharma.
What is Novavax?
Novavax's catalysts are the COVID/flu-combo program, seasonal-vaccine partnerships, and royalty momentum from its vaccine platform.
Which conditions is Novavax targeting with Novavax?
Novavax is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Novavax describe recent progress with Novavax?
Novavax's catalysts are the COVID/flu-combo program, seasonal-vaccine partnerships, and royalty momentum from its vaccine platform.
What future catalysts are investors watching for Novavax?
Novavax's catalysts are the COVID/flu-combo program, seasonal-vaccine partnerships, and royalty momentum from its vaccine platform. The company still needs the platform to keep broadening.